SCENESSE - Afamelanotide -
EMEA/H/C/002548/II/0052, Orphan
Clinuvel Europe Limited, Rapporteur: Janet
Koenig, PRAC Rapporteur: Martin Huber ,
“Update of section 4.2 of the SmPC in order to
update the posology recommendations by
removing the current recommendation of a
maximum of four implants per year, based on a
literature review and analysis of safety data.
The Package Leaflet is updated accordingly. The
RMP version 9.8 has also been submitted. In
addition, the MAH took the opportunity to
introduce a minor editoria
https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf
SCENESSE - Afamelanotide -EMEA/H/C/002548/II/0052,...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.16 |
Change
0.090(0.60%) |
Mkt cap ! $759.1M | |||
| Open | High | Low | Value | Volume |
| $15.12 | $15.44 | $15.02 | $1.063M | 70.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 126 | $15.14 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 764 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |